Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(27 sites)
United States
Emory University Hospital, Atlanta, Georgia Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405, Louisville, Kentucky Brazil
Hospital São Rafael, Salvador, Estado de Bahia Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba Ruschel Medicina e Pesquisa Clínica, Rio de Janeiro A.C. Camargo Cancer Center, São Paulo Hospital Amaral Carvalho, São Paulo Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo Hospital Israelita Albert Einstein, São Paulo Hospital Samaritano, São Paulo Hospital Sírio-Libanês, São Paulo Germany
Krankenhaus Nordwest Klinik für Onkologie und Hämatologie, Frankfurt am Main, Hesse Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care, Stuttgart Poland
Szpital Specjlistyczny, Grudziądz Małopolskie Centrum Medyczne, Krakow Spain
Hospital ICO, Trias i Pujol, Badalona, Barcelona Hospital de la Santa Creu i Sant Pau, Dep Hematologia, Barcelona Hospital Universitari Vall d'Hebron, Barcelona Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona Hospital General Universitario Gregorio Marañon-Oncología Médica, Madrid Hospital Universitario HM Sanchinarro, Madrid University Hospital Fundacion Jimenez Diaz, Madrid Hospital Universitario Virgen de la Arrixaca, Murcia Hospital University Virgen Macarene, Seville Sweden
Department of Oncology, Skåne University Hospital, Lund Department of Oncology, Academical Hospital, Uppsala